Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChiCTR2200056993Phase 4Recruiting
Phase 4, open-label, single-arm trial of venetoclax and azacitidine in myelodysplastic syndrome (MDS), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: overall response rate. Started Jun 2021; status: recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on ChiCTR2200056993.